Webinar Video | Life Sciences Session #1: What’s new in the parallel world of parallel trade?

In our first Life Sciences Session, our experts Philippe de Jong and Kirian Claeyé talk you through a number of recent decisions and developments in the field of parallel trade of pharmaceuticals, medical devices and plant protection products, including:
- The rebranding of generics to original brand reference products
- The impact of the falsified medicines framework on parallel trade
- Further points of attention when verifying in light of the BMS conditions
Recommended articles
New year, new policy: CPVO updates its public access to documents policy
The Community Plant Variety Office (CPVO) recently revised its public access to documents policy to align with the European Union (EU)’s evolving transparency standards. Effective since 15 January 2025, the new policy seeks to ensure broad access to all documents that the CPVO holds, while protecting private parties’ commercial interests. In particular, a system of prior confidentiality requests has been put in place for applicants of Community plant variety rights (CPVR).
Read onEuropean Commission proposes new PPP labelling requirements
On 6 January 2025, the European Commission published a draft proposal aimed at further harmonising labelling requirements for plant protection products (PPPs) in the European Union (EU). The proposal intends to repeal the existing labelling rules and introduce certain new requirements, including mandatory digital labelling. Since the draft proposal has not yet been formally adopted, some changes to the final version remain possible.
Read onCJEU C-793/22 Biohemp – Indoor Cannabis Cultivation: The CJEU Weighs in
The Cannabis sativa L. plant serves a wide range of purposes, many of which are uncontroversial. It can be grown in the EU, in which context it is commonly called ‘hemp’. The plant notably produces cannabidiol (CBD), which the Court of Justice of the European Union has unequivocally ruled is not a narcotic drug. Nonetheless, some EU Member States remain reluctant to accept hemp cultivation.
Read on